NGNE – neurogene inc. (US:NASDAQ)
Stock Stats
News
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome [Yahoo! Finance]
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Form 8-K Neurogene Inc. For: Jan 12
Form SCHEDULE 13G Neurogene Inc. Filed by: Trails Edge Capital Partners, LP
Form SCHEDULE 13G/A Neurogene Inc. Filed by: EcoR1 Capital, LLC
Form 8-K Neurogene Inc. For: Nov 12
Form 8-K Neurogene Inc. For: Nov 06
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.